Krebs Biochemicals and Industries Limited has informed the Exchange regarding 'Board comments on fine levied by Exchanges'.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE and BSE levied a fine on Krebs Biochemicals for non-compliance with Regulation 17(1) of the SEBI Listing Regulations during the quarter ended 31st March 2025. The issue was related to the Board composition — specifically, the company failed to have the required number of Independent Directors on its Board. All four Independent Directors retired one by one between 1st January and 31st March 2025, and there was a 33-day delay in appointing replacements. The company has since appointed four new Independent Directors on 4th February 2025 to rectify the shortfall. The Board stated that finding suitable independent directors meeting selection criteria took longer than expected. The Board has assured steps to avoid such lapses in future.
This is a minor penalty for a corporate governance lapse rather than a financial or operational issue. The actual fine amount is not disclosed in the filing but exchange fines for such non-compliance are typically small. The non-compliance has already been rectified, so the long-term impact on shareholders should be limited, though it reflects weak governance oversight.